MultiCell Technologies Inc (MCET): Latest Information Update: 28 Sep 2018:...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	40567
Boards Moderated	4
Alias Born	10/24/2013

TPX

Re: None

Monday, 10/08/2018 1:09:02 PM

Monday, October 08, 2018 1:09:02 PM

Latest Information Update: 28 Sep 2018: Research programme: anticancer and antiviral therapeutics - MultiCell Technologies

Alternative Names: Ig-NP; IgP therapeutic; MCT-475; MCT-485
Latest Information Update: 28 Sep 2018

At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Immunoglobulin fusion proteins; Recombinant fusion proteins; RNA
Mechanism of Action Apoptosis stimulants; Immunomodulators; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 3 agonists; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor agonists; Tumour necrosis factor alpha stimulants
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases
No development reported Cancer; Liver cancer; Viral hepatitis
Most Recent Events
28 Sep 2018 No recent reports of development identified for preclinical development in Viral-hepatitis in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Liver cancer in USA (Parenteral)

https://adisinsight.springer.com/drugs/800025804

>>> Trip Advisor IS A GROWING STOCK PICK BOARD NOW <<<